Agilent Technologies (NYSE:A) Issues FY 2026 Earnings Guidance

Agilent Technologies (NYSE:A) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 6.000-6.100 for the period, compared to the consensus EPS estimate of 5.970. The company issued revenue guidance of $7.4 billion-$7.5 billion, compared to the consensus revenue estimate of $7.4 billion. Agilent Technologies also updated its Q3 2026 guidance to 1.480-1.500 EPS.

Analysts Set New Price Targets

A number of research firms recently commented on A. Morgan Stanley reduced their price target on Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Royal Bank Of Canada started coverage on Agilent Technologies in a report on Wednesday. They set an “outperform” rating and a $153.00 price objective for the company. Barclays reduced their price objective on Agilent Technologies from $150.00 to $140.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. Robert W. Baird boosted their price target on Agilent Technologies from $155.00 to $156.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Wall Street Zen cut Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Agilent Technologies has a consensus rating of “Buy” and a consensus target price of $162.40.

Agilent Technologies Price Performance

Shares of NYSE:A traded up $0.74 during trading on Wednesday, hitting $115.82. 2,899,904 shares of the company were exchanged, compared to its average volume of 2,183,498. The business’s 50 day moving average is $114.91 and its 200-day moving average is $129.01. The company has a market capitalization of $32.73 billion, a P/E ratio of 25.57, a price-to-earnings-growth ratio of 2.42 and a beta of 1.22. The company has a quick ratio of 1.59, a current ratio of 2.07 and a debt-to-equity ratio of 0.44. Agilent Technologies has a 1-year low of $108.35 and a 1-year high of $160.27.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.09. The company had revenue of $1.84 billion during the quarter, compared to the consensus estimate of $1.80 billion. Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Equities analysts forecast that Agilent Technologies will post 5.95 earnings per share for the current year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Tuesday, June 30th will be issued a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, June 30th. Agilent Technologies’s dividend payout ratio is presently 22.52%.

More Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent raised its FY 2026 outlook, guiding for EPS of $6.00-$6.10 and revenue of $7.4 billion-$7.5 billion, both in line to slightly above Wall Street expectations. The company also guided Q3 EPS to $1.48-$1.50 on revenue of $1.8 billion-$1.9 billion, signaling stable demand and execution.
• Positive Sentiment: Royal Bank of Canada initiated/started coverage with an Outperform rating and a $153 price target, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: Robert W. Baird also raised its price target to $156 and reiterated an Outperform rating, reinforcing analyst confidence ahead of the next earnings cycle. Benzinga
• Neutral Sentiment: Recent product and conference announcements, including new GC systems, a MAM solution for biopharma quality control, and cancer research showcases, highlight ongoing innovation but are less likely to move the stock immediately.

Institutional Trading of Agilent Technologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC boosted its position in Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after acquiring an additional 1,652,244 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Agilent Technologies by 132.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock worth $277,807,000 after purchasing an additional 1,340,161 shares in the last quarter. Morgan Stanley boosted its position in shares of Agilent Technologies by 15.9% during the 4th quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock worth $686,049,000 after purchasing an additional 692,202 shares in the last quarter. Invesco Ltd. boosted its position in shares of Agilent Technologies by 32.0% during the 4th quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock worth $352,519,000 after purchasing an additional 627,804 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its position in shares of Agilent Technologies by 639.4% during the 2nd quarter. Lazard Asset Management LLC now owns 678,718 shares of the medical research company’s stock worth $80,093,000 after purchasing an additional 586,931 shares in the last quarter. 87.41% of the stock is currently owned by institutional investors and hedge funds.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.